<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342055</url>
  </required_header>
  <id_info>
    <org_study_id>LG-ESCL002</org_study_id>
    <nct_id>NCT01342055</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers</brief_title>
  <official_title>Phase I Study of Apetrol ES and Megace® in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Open Label, Single dose, Cross-over, Phase I Trial to Investigate Safety and
      Pharmacokinetics of Apetrol ES and Megace® under Fed Conditions in Healthy Male Volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax, AUClast</measure>
    <time_frame>Day 34</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf, Tmax, t1/2(beta)</measure>
    <time_frame>Day 34</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apetrol ES</intervention_name>
    <description>sequences of administered drugs</description>
    <arm_group_label>Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg</arm_group_label>
    <arm_group_label>Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg</arm_group_label>
    <arm_group_label>Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg</arm_group_label>
    <arm_group_label>Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg</arm_group_label>
    <arm_group_label>Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg</arm_group_label>
    <arm_group_label>Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is a healty male between 20 and 55 years old

          -  Has BMI result between 19 and 26 kg/m2 at screening

          -  Is willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures

          -  Agrees to use an adequate means of contraception during clinical trials

        Exclusion Criteria:

          -  Has had a serious illness or medical condition(s) regarding liver, kidney,
             gastrointestines, pulmonary systems, etc.

          -  Has had a medical history of gastrointestinal diseases which might affect drug
             absorption (i.e. Crohn's disease, ulcer) or surgical history.

          -  Is allergic against Megestrol acetate or other drugs (Aspirin, NSAIDs, Antibiotics,
             etc.) or against foods, or has an clinically serious allergic history
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <last_update_submitted>October 8, 2012</last_update_submitted>
  <last_update_submitted_qc>October 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

